NCT00553800

Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer

Phase II Study of Bevacizumab and Erlotinib in Elderly Patients With Advanced Non-Small Lung Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Fox Chase Cancer Center · Academic / Other
• Sex: All
• Age: 70 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the combination of bevacizumab and erlotinib in elderly patients with advanced non-small cell lung cancer.

Detailed description

There is no definite evidence of a superior therapy for advanced non-small cell lung cancer in elderly patients. With the exception of one known study, single agent erlotinib has not been studied exclusively in the elderly and the combination of erlotinib and bevacizumab has never been studied exclusively in the treatment naive elderly. This is an important population that needs less toxic therapies.

Conditions

• Carcinoma, Non-Small-Cell Lung

Interventions

Type	Name	Description
DRUG	bevacizumab
DRUG	Erlotinib

Timeline

• Start date: 2007-07-05
• Primary completion: 2011-01-12
• Completion: 2011-06-01
• First posted: 2007-11-06
• Last updated: 2022-07-12
• Results posted: 2022-07-12

Locations

7 sites across 1 country: United States